UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2009
MOCON, INC.
(Exact name of registrant as specified in its charter)
Minnesota | | 000-09273 | | 41-0903312 |
(State or Other Jurisdiction of
Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification
Number) |
7500 Boone Avenue North
Minneapolis, MN | | 55428 |
(Address of Principal Executive Offices) | | (Zip Code) |
(763) 493-6370
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On December 21, 2009, MOCON, Inc. (“MOCON”) entered into a Subscription and Shareholders Agreement (the “Agreement”) with Enterprise Ireland, Glanbia Enterprise Fund Limited, Parties Named in Schedule 1 to the Agreement and Luxcel BioSciences Limited (“Luxcel”) whereby, MOCON, through a newly formed wholly owned subsidiary, will acquire 1,250,000 A Preferred Ordinary Shares, which will represent approximately 16.9% of the outstanding equity in Luxcel, for €2,500,000 (or approximately $3,550,000). Subject to the terms and conditions of the Agreement, MOCON expects to complete the acquisition of these shares on or about January 15, 2010.
In connection with the Agreement, MOCON also anticipates entering into a supply agreement with Luxcel whereby MOCON will purchase from Luxcel certain components and supplies that MOCON will use in its instrumentation products.
The aforementioned description of the Agreement is qualified in its entirety by reference to the complete terms of the Agreement, a copy of which is included as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
10.1 | | Subscription and Shareholders Agreement dated December 21, 2009, by and among the Parties Named in Schedule 1, MOCON, Inc., Enterprise Ireland, Glanbia Enterprise Fund Limited and Luxcel BioSciences Limited (filed herewith) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | MOCON, INC. |
| |
Dated: December 23, 2009 | By: | /s/ Darrell B. Lee |
| | Darrell B. Lee |
| | Vice President, Chief Financial Officer, |
| | Treasurer and Secretary |
| | | |
3
MOCON, INC.
CURRENT REPORT ON FORM 8-K
INDEX TO EXHIBITS
Exhibit No. | | Description | | Method of Filing |
| | | | |
10.1 | | Subscription and Shareholders Agreement dated December 21, 2009, by and among the Parties Named in Schedule 1, MOCON, Inc., Enterprise Ireland, Glanbia Enterprise Fund Limited and Luxcel BioSciences Limited | | Filed herewith |
4
